Gold R, Lepow M L, Goldschneider I, Draper T F, Gotschlich E C
J Infect Dis. 1978 Dec;138(6):731-5. doi: 10.1093/infdis/138.6.731.
Infants were immunized with group A Neisseria meningitidis polysaccharide vaccine at two, four, and six months of age. Two lots of group A vaccine that differed in molecular weight were used; lot no. 1980A was of significantly larger molecular size than lot no. A-7. No significant adverse reactions occurred. The geometric mean concentration of serum antibody to group A N. meningitidis one month after the third dose of lot no. 1980A was 0.89 microgram/ml, nearly twice the concentration induced by lot no. A-7 (0.48 microgram/ml). When the infants were 12 months of age, concentrations of antibody in both groups had declined to similar levels, which were still greater than the mean concentration of antibody in unimmunized children. By 18 months of age, the antibody levels of immunized and unimmunized infants were the same. The three-dose schedule resulted in significantly lower concentrations of antibody than previously studied schedules of two doses given three to four months apart.
婴儿在2个月、4个月和6个月大时接种了A群脑膜炎奈瑟菌多糖疫苗。使用了两批分子量不同的A群疫苗;1980A批次的分子大小明显大于A - 7批次。未发生明显不良反应。在接种1980A批次第三剂疫苗一个月后,血清中抗A群脑膜炎奈瑟菌抗体的几何平均浓度为0.89微克/毫升,几乎是A - 7批次诱导浓度(0.48微克/毫升)的两倍。当婴儿12个月大时,两组的抗体浓度均下降到相似水平,仍高于未免疫儿童的抗体平均浓度。到18个月大时,免疫和未免疫婴儿的抗体水平相同。与之前研究的间隔三到四个月接种两剂的方案相比,三剂接种方案导致的抗体浓度显著更低。